**PepTrack™**
—
Enabling Peptide Library Technologies for
> T-cell Assays
> Peptide Vaccine Development
> CD4⁺ and CD8⁺ Epitope Mapping
> Vaccine Efficacy Testing

**Innovative Peptide Solutions**
The most efficient peptide library technology on the market. Designed to address the specific needs of T-cell assays in all development phases of novel vaccines and peptide biomarker discovery.

---

**Discuss your project with us**
Please fax back to +49-30-6392-5501

**My field of application is**
- [ ] Monitoring vaccination trials
- [ ] Epitope discovery (B-cell)
- [ ] Epitope discovery (T-cell)
- [ ] Immunomonitoring
  ( ) infectious diseases ( ) allergies
  ( ) autoimmune diseases ( ) organ transplantation
- [ ] Biomarker discovery
- [ ] Adoptive immunotherapy
- [ ] T-cell assays

other: ____________________________

**I wish to receive more information about JPT’s**
- [ ] Peptides
- [ ] Peptide arrays
- [ ] Customized PepMixes™, please specify antigen: ________
- [ ] Ready-to-use PepMixes™
- [ ] Peptide libraries
- [ ] Peptide scans
- [ ] B-cell epitope mapping service
- [ ] Proteomics
- [ ] Enzyme profiling

other/please specify: ____________________________

[ ] I want to receive JPT’s newsletter

May we contact you by phone or mail?

Name

Inst./Company                                    Town/Country

Phone Number

Official Email Address

---

**Find your JPT product at one glance**

- **Immuno Tools**
  - PepStar™ Microarrays
  - PepSpots™ Array Service
  - PepMix™
  - PepTrack™ Peptide Libraries
  - RepliTope™

- **Peptides & Arrays**
  - PepStar™ Microarrays
  - PepSpots™ Array Service
  - PepTrack™ Peptide Libraries
  - Custom Peptides
  - Macroscale Peptide Sets
  - Microscale Peptide Sets
  - BioTides™
  - Peptide Conjugates

- **Proteomics & Enzyme Profiling Tools**
  - SpikeTides™
  - Kinase Profiling Tools
  - Phosphatase Profiling Tools
  - Protease Profiling Tools
  - Macroscale Peptide Sets
  - PepStar™ Microarrays

---

**Enabling Peptide Library Technologies for**
> T-cell Assays
> Peptide Vaccine Development
> CD4⁺ and CD8⁺ Epitope Mapping
> Vaccine Efficacy Testing

---

JPT Peptide Technologies
www.jpt.com | peptide@jpt.com
JPT’s PepTrack™ peptide libraries combine proprietary synthesis methodology capable of producing tens of thousands of peptides in numerous configurations at extremely flexible specifications with in-depth knowledge of the exacting and evolving requirements of T-cell assays in discovery research and clinical trials.

**PepTrack™ Options**

- **Fast Track** – proteome spanning peptide libraries for T-cell epitope discovery
- **Research Track** – economic and reliable tool for epitope mapping
- **Discovery Track** – guaranteed purity for immune monitoring
- **Trial Track** – highest quality for efficacy trials

**Applications**
- T-cell assays (ELISPOT, ICS, CFC…)
- T-cell epitope discovery
- Peptide vaccine development
- T-cell epitope mapping and validation
- Immune monitoring
- Optimization and validation of T-cell assays
- Vaccine efficacy testing
- Adoptive immunotherapy

**Benefits of PepTrack™**
- Unprecedented economy from 7 $/€ per peptide
- Optimized protocols to inhibit false positives in T-cell assays
- Documented procedures designed to avoid toxic contaminants
- No peptide contaminants from foreign antigens
- No cross contamination
- Variable specifications and formats
- Validated protocols for pooling and aliquoting
- Freeze dried aliquots for enhanced stability

**Option Purity QA/QC Scale Length Delivery Unit Pricing**

<table>
<thead>
<tr>
<th>Option</th>
<th>Purity</th>
<th>QA/QC</th>
<th>Scale</th>
<th>Length</th>
<th>Delivery</th>
<th>Unit Pricing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial</td>
<td>&gt; 80%* guaranteed</td>
<td>LC-MS</td>
<td>&gt; 1mg</td>
<td>7-15 aa</td>
<td>3 weeks</td>
<td>from 69 $/€</td>
</tr>
<tr>
<td>Discovery</td>
<td>&gt; 70% guaranteed</td>
<td>LC-MS</td>
<td>1-5mg</td>
<td>7-15 aa</td>
<td>3 weeks</td>
<td>from 45 $/€</td>
</tr>
<tr>
<td>Research</td>
<td>main product = target</td>
<td>100% LC-MS</td>
<td>1-5mg</td>
<td>7-15 aa</td>
<td>2 weeks</td>
<td>from 25 $/€</td>
</tr>
<tr>
<td>Fast</td>
<td>unpurified 5% LC-MS**</td>
<td>50-250nmol</td>
<td>7-15 aa</td>
<td>2 weeks</td>
<td>from 7 $/€</td>
<td></td>
</tr>
</tbody>
</table>

* higher purities such as > 90%, > 95% and > 97% are available
** complete QC optional

**Quality Assurance**

JPT is committed to highest quality standards. All processes run under an ISO 9001:2008 certified quality management system and the company was successfully GCLP audited. We encourage our clients to visit and inspect our state of the art facilities.

**Testimonials**

“I have been collaborating with JPT for several years. Their unique peptide library technologies and knowledge of specific peptide requirements for T-cell assays made them a valuable, long-term partner in our efforts to develop novel adoptive immunotherapy approaches to prevent and treat viral infections post-transplant as well as for the treatment of virus and non-virus-associated malignancies. Furthermore, their reagents allow us to precisely monitor and track specific T-cell populations post-infusion.”

Ann M. Leen, PhD, Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX

“We utilize JPT’s peptide libraries and pools for T-cell epitope mapping and immune monitoring applications such as ELISPOT and ICS, as well as CFC. The combination of synthesis economy, quick turnaround time and tailored specifications are key to our success. JPT’s scientific competence is invaluable for all institutions planning to employ peptides in immuno assays for research or clinical setups.”

Johannes Hampf, PhD, Anza Therapeutics, Inc, Concord, CA, USA

**References**

- “Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086” Mascioni et al., The Journal of Biological Chemistry (2009)
- “Peptide Impurities in Commercial Synthetic Peptides and their Implications for Vaccine Trial Assessment” Currier et al., Clinical and Vaccine Immunology (2008)
- “Magnitude, Breadth, And Functional Profile of T-Cell Responses During Human Immunodeficiency Virus Primary Infection with B and BF Viral Variants” Turk et al., Journal of Virology (2008)